anticancer/obesity

BACKGROUND OF THE INVENTION This invention is a continuation-in-part of copending U.S. Application Ser. No. 519,550, filed on Aug. 2, 1983. This invention described herein was made in the course of work under a grant or award sponsored in part by the National Institutes of Health. This invention

BACKGROUND OF THE INVENTION This invention described herein was made in the course of work under a grant or award sponsored in part by the National Institutes of Health. This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity,

BACKGROUND OF THE INVENTION This invention described herein was made in the course of work under a grant or award sponsored in part by the National Institutes of Health. This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity,

BACKGROUND OF THE INVENTION This invention described herein was made in the course of work under a grant or award sponsored in part by the National Institutes of Health. This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity,

TECHNICAL FIELD This invention is in the field of pharmaceuticals and chemical industries. In particular, this invention relates to new anticancer and anti-obesity agents based on the cyclic peptide compounds. The invention also includes its preparation and application method for treating cancer and

BACKGROUND A major challenge facing biological researchers in the 21.sup.st century is the functional characterization of the large number of unannotated gene products identified by genome sequencing efforts. Many proteins partly or completely uncharacterized with respect to their biochemical

BACKGROUND OF THE INVENTION The present invention relates to novel xanthone derivatives, a process of preparing the same, pharmaceutical compositions comprising the same, and their use as pharmaceuticals, hair growth promotion agents, weight reduction and anti-obesity agents, and anti-inflammatory

BACKGROUND OF THE INVENTION This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity, anti-diabetic, and hypolipidemic agents and useful for combatting coronary diseases. Dehydroepiandrosterone (DHEA) and DHEA-sulfate are major

BACKGROUND OF THE INVENTION This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity, anti-diabetic, and hypolipidemic agents and useful in combatting coronary diseases. Dehydroepiandrosterone (DHEA) and DHEA-sulfate are major

This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity, anti-diabetic and hypolipidemic agents. Dehydroepiandrosterone (DHEA) and DHEA-sulfate are major adrenal secretory products in humans. The plasma concentration of

BACKGROUND OF THE INVENTION This invention relates to novel steroids and more particularly to androsterone derivatives useful as anti-cancer, anti-obesity, anti-diabetic and hypolipidemic agents. Dehydroepiandrosterone (DHEA) and DHEA-sulfate are major adrenal secretory products in humans. The

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to bioactive proteins, peptides and enzymatic hydrolysates from rice bran and use thereof, and more particularly to a purified, unmodified and modified bioactive pentapeptide from heat stabilized defatted rice

TECHNICAL FIELD The present disclosure pertains generally to biomedical research. More specifically, the present disclosure pertains to a mouse with genetic advantages for biomedical research. BACKGROUND AND SUMMARY There are hundreds of pathological mutants in mice and rats, and many of these are

BACKGROUND OF THE INVENTION This invention relates to vitamin D compounds, and more particularly to 17,20(E)-dehydro vitamin D analogs and their pharmaceutical uses, and especially 17(E)-1.alpha.,25-dihydroxy-17(20)-dehydro-2-methylene-19-norvitamin D.sub.3, its biological activities, and its

BACKGROUND OF THE INVENTION This invention relates to vitamin D compounds, and more particularly to 17,20(E)-dehydro vitamin D analogs and their pharmaceutical uses, and especially 17(E)-1.alpha.,25-dihydroxy-17(20)-dehydro-2-methylene-19-norvitamin D.sub.3, its biological activities, and its